Myostatin as a therapeutic target for musculoskeletal disease.
Bradley
L
L
Discovery Research, Wyeth Research, Cambridge, MA 02140, USA.
Yaworsky
P J
PJ
Walsh
F S
FS
D030301:Activin Receptors, Type II / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D038681:Follistatin / Q000627:therapeutic use; D056572:Histone Deacetylase Inhibitors; D006706:Homeostasis; D006801:Humans; D008954:Models, Biological; D018482:Muscle, Skeletal / Q000503:physiopathology; D009140:Musculoskeletal Diseases / Q000235:genetics / Q000503:physiopathology / Q000628:therapy*; D009154:Mutation; D055435:Myostatin; D010446:Peptide Fragments / Q000627:therapeutic use; D015398:Signal Transduction; D016212:Transforming Growth Factor beta / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000276:immunology / Q000502:physiology
D000911:Antibodies, Monoclonal; D038681:Follistatin; D056572:Histone Deacetylase Inhibitors; C525911:MSTN protein, human; D055435:Myostatin; D010446:Peptide Fragments; D016212:Transforming Growth Factor beta; D030301:Activin Receptors, Type II